Product Description
Riboflavin (also known as vitamin B2) is one of the B vitamins, which are all water soluble. Riboflavin is naturally present in some foods, added to some food products, and available as a dietary supplement.
Mechanisms of Action: Carbohydrate Metabolism Cofactor,Lipid Metabolism Cofactor,Protein Metabolism Cofactor,Glutathione Reductase Cofactor,XO Cofactor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral,Ophthalmic,Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Dominican Republic | Ecuador | Egypt | Estonia | Finland | France | Germany | Greece | Hong Kong | India | Indonesia | Ireland | Jordan | Korea | Lebanon | Malaysia | Malta | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Serbia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Keratoconus | Vitamin D Deficiency | Vitamin D Deficiency | Vitamin D Deficiency
Known Adverse Events: Eye Pain | Pain Unspecified | Photophobia | Keratoconjunctivitis Sicca | Corneal Opacity | Keratitis | Keratoconus | Diplopia | Dizziness | Headache | Erythema | Pruritus | Anaphylaxis | Angioedema | Urticaria | Edema
Company: Glaukos
Company Location: SAN CLEMENTE CA 92672
Company CEO: Thomas W. Burns
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: United States
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Corneal Neovascularization|Keratoconus
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| NCT03922542 | P3 |
Recruiting |
Keratoconus |
2026-06-01 |
|
| NCT04787471 | P3 |
Recruiting |
Corneal Neovascularization |
2025-07-15 |